Eli Lilly and Company (LLY)

Rating: SELL

SELL (5-tier) · mature cash generator · conviction: medium

EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).

Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.

General research for a skeptical institutional reader. Not personalised investment advice; no position sizing or trade instructions. Figures as of the analysis date; verify before acting.

Investment Committee Summary

📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.

Rating Bridge

Rating = SELL because:

• Probability-weighted scenario value implies -11% vs spot
• Monte Carlo median implies -18% vs spot
• DCF fair value implies -30% vs spot — but this is terminal-value sensitive (exit-multiple $871 vs Gordon $612, 30% apart), so it carries less weight
• Bear case (Structural — Patent Cliff (LOE) / IRA Pricing Erosion) downside is -60% vs spot
• Net: reward/risk of 0.4× warrants a Sell.

Investment Thesis

At $1,199 on roughly $37 forward earnings, the market pays about 33 times for Lilly, well above the 15-times peer median for JNJ, MRK, PFE and BMY. Spot therefore prices sustained mid-teens franchise compounding and a durable incretin lead, not a mature-pharma cash cow. The engine is more cautious. Its probability-weighted target of $1,126 sits below spot, so the rating is HOLD. Two anchors pull it down: an independent DCF of $881 on an 8.5 per cent WACC, and a peer-multiple cross-check implying $298 to $543. The single segment carries a 0.509 operating margin and 4 per cent base growth; the premium the engine grants lives in the multiple, not in a heroic earnings path. Roughly 86 per cent of the Monte Carlo variance is the multiple itself, which is the honest tell: the position is a bet on the re-rating holding. The most damaging risk is a manufacturing build near $8 billion a year against $2 billion of depreciation — capacity that only pays if incretin volume keeps compounding.

The dashboard below is the whole argument on one page: spot ($1,236) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The highest-probability bear leg is the structural patent-cliff and IRA-erosion state, which the cluster house view puts at 37 per cent. The mechanism is concrete. Incretin is now the earnings engine, and it faces credible oral and injectable competition alongside IRA price negotiation on the legacy base. If share slips while negotiated prices step down, revenue can roll over even as unit demand stays firm. The $8-billion-a-year capacity build then de-levers: fixed manufacturing carries lower throughput, so margin compresses from 0.509 toward the low-0.40s. A market that paid 33 times for compounding re-rates toward the mid-pharma high-teens. Earnings and multiple fall together, and the structural target of $495 sits below the 52-week low by construction.

Key Debate

P/E Multiple explains 86% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q1): management +0.49 vs analyst floor +0.00 → delta +0.49 (n=30 mgmt / 13 Q&A; 71th pctile across the S&P book, z +0.6).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 1000 articles): avg ticker sentiment +0.25 (bullish 22% / bearish 0%)

Scenario Analysis

The tree runs from a structural 'Structural — Patent Cliff (LOE) / IRA Pricing Erosion' downside ($494) to a 'Bull — Blockbuster / Pipeline Re-Rate' bull case ($1,885); the probability-weighted blend (PWEV $1,100) is -11% versus spot.

Scenario rationale — what each probability buys (the driver path behind every target):

• Structural — Patent Cliff (LOE) / IRA Pricing Erosion (20%, $494). Structural impairment — patent cliff (LOE) / IRA pricing erosion: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 495.27; probability: 0.2.
• Pipeline Setback / Pricing Pressure (17%, $846). Cyclical downturn — drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory weakens for 1–2 years before normalising. Drivers — implied_target: 841.06; probability: 0.17.
• Base — Pipeline Offsets LOE (35%, $1,160). Mid-cycle — normalised drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory; disciplined capital allocation; steady returns. Drivers — implied_target: 1168.13; probability: 0.35.
• Growth — Launch / Indication Expansion (20%, $1,505). Upside — pipeline launches + indication expansion lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 1576.98; probability: 0.2.
• Bull — Blockbuster / Pipeline Re-Rate (8%, $1,885). Upside tail — sustained tight conditions or a structural re-rate on pipeline launches + indication expansion. Drivers — implied_target: 1991.67; probability: 0.08.

Valuation Triangulation

Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the distribution, not a point

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $1,017 and 28% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (86% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 26x terminal FCF multiple → $871. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median forward multiple (P/E 14.955000000000002x) implies $543. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.

Across all anchors the spread is 92% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Pharma

This name sits in the Health Pharma as a biopharma. drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: LLY (biopharma) · JNJ (biopharma) · ABBV (biopharma) · MRK (biopharma) · AMGN (biopharma) · GILD (biopharma) · PFE (biopharma) · VRTX (biopharma) · BMY (biopharma) · REGN (biopharma) · BIIB (biopharma) · INCY (biopharma) · VTRS (biopharma)

Mapping note: name-level 'Structural — Patent Cliff (LOE) / IRA Pricing Erosion' (20%) + 'Pipeline Setback / Pricing Pressure' (17%) map to cluster Patent Cliff / IRA Pricing Erosion (37%); name-level 'Growth — Launch / Indication Expansion' (20%) + 'Bull — Blockbuster / Pipeline Re-Rate' (8%) map to cluster Upside — Launches / Pipeline Re-Rate (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Patent Cliff / IRA Pricing Erosion () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The health_pharma cycle is the shared macro driver. Driver — drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 6% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $142B + PV(terminal) $677B = EV $819B; + net cash → equity $780B ÷ diluted shares 0.90B = $871/share (exit-multiple terminal).

• Gordon (perpetuity-growth) terminal at 2.5% → $612/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 15% vs WACC 8% → above WACC — the build is value-creative.

Peer set

Peer-median fwd P/E → $543; EV/Rev → $297.

Weighted fair-value math

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Biopharma multiple (AI re-rating) (base 31x)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 0.9% of revenue; cash conversion (OCF/NI) 82% — cash-backed.

Catalyst Calendar

• 2026-08-06 (~29d) — Quarterly earnings — est. EPS $8.98 (AV EARNINGS_CALENDAR)
• 2026-09-30 (~84d) — Oral GLP-1 (orforglipron) pivotal / regulatory-filing readout (authored)
• 2026-11-12 (~127d) — GLP-1 manufacturing-capacity expansion online milestone (authored)
• 2027-01-15 (~191d) — IRA Medicare price-negotiation inclusion / drug-list update (authored)

Forecast Track Record

• EPS surprise: beat 75.0% of the last 8 quarters; average surprise +10.8%.

Competitive Moat

Wide moat. Lilly's moat is patent-protected incretin franchises (tirzepatide) plus manufacturing scale in a supply-constrained GLP-1 market and a deep obesity/diabetes pipeline — a genuinely wide but time-limited moat, since patents expire. The ~33x multiple prices durable mid-teens compounding; that terminal multiple is only justified if next-gen assets (oral GLP-1, amylin combos) refill the moat before LOE. Falsifiable: if a pivotal next-gen readout fails or an oral incretin competitor takes share, the wide-but-fading moat argues for terminal compression toward the ~15x mature-pharma peer median.

Moat sources:

• Patent-protected tirzepatide (Mounjaro/Zepbound) incretin franchise
• GLP-1 manufacturing capacity scarcity as a near-term barrier
• Deep incretin/obesity pipeline (orforglipron oral, retatrutide, amylin)
• Moat is time-limited — patent expiry means terminal durability is not assured

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

What the Market Is Pricing In

At the current price, the market pays 27.8× forward EPS, vs the house DCF terminal 26.0×, and a peer median 14.955000000000002×. The house DCF sits 30% below spot, so the market is pricing in more than the house case — roughly 3.1pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily event-driven.

Peer Quality & Weighting

Quality-weighted forward P/E: 18.1× (simple median 14.955000000000002×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $619–$1,183, centre $856 (-31% vs spot); spot sits at the 109th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

Reward/risk compares triangulated upside against the probability-weighted bear target, not the extreme tail. Bull case (Bull — Blockbuster / Pipeline Re-Rate): $1,885.

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Revenue CAGR ±3pp (250.0); Terminal × ±15% (227.0); Op margin ±3pp (102.0); WACC ±1pp (78.0); Capex intensity ±15% (65.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Source Log

Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.

Load-Bearing Assumptions

DCF: WACC 8%, terminal multiple 26×, FY+5 revenue $85B. Triangulation leans 41% on DCF, 29% on PWEV.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Total revenue year-on-year growth < 0.015 (2 consecutive prints → Patent Cliff / IRA Pricing Erosion). Base case rests on mid-single-digit growth as incretin volume offsets LOE. Growth falling below the Base/Pipeline-Setback midpoint for two quarters signals the offset is failing.
• Non-GAAP operating margin < 0.48 (2 consecutive prints → Patent Cliff / IRA Pricing Erosion). Base op margin is 0.509. A print below the Pipeline-Setback level for two quarters indicates the manufacturing build is not being absorbed and fixed cost is de-levering.
• Tirzepatide-franchise net revenue growth < 0.0 (2 consecutive prints → Patent Cliff / IRA Pricing Erosion). The thesis concentrates on the incretin franchise. Two quarters of outright decline in the lead franchise would confirm competitive or reimbursement erosion rather than a supply-timing effect.
• Capex as a share of revenue > 0.13 (2 consecutive prints → Mid-Cycle — Pipeline Offsets LOE). Trailing capex is already near $7.8B on $72B revenue. A sustained step above ~13% without matching revenue would signal a value-dilutive build where the capacity is not being filled.
• Late-stage pipeline read-out outcome == failure (single event → Patent Cliff / IRA Pricing Erosion). A pivotal Phase-3 miss on a key incretin or Alzheimer's programme removes an indication-expansion leg that the Growth and Bull paths depend on, forcing a re-rate toward the setback case.

Fact / Inference / Speculation

• FACT: Spot $1,236; 52-week range $619–$1,183; engine rating SELL; base-case target $1,126 (-9%). (source: Alpha Vantage 2026-06-27, 8 July 2026)
• INFERENCE: Triangulated FV $926 (-25% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Recommendation: SELL

Defensive: rating SELL; triangulated fair value $926 (-25% vs spot) — the risk/reward is skewed to the downside on P/E Multiple. The debate is P/E Multiple — fundamentally a multiple/regime call.

Disclosures & Limitations

This report is for informational and research purposes only. It is not personalised investment advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.

• No suitability assessment has been performed for any individual.
• Market data may be delayed or inaccurate; figures are as of the analysis date.
• Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
• Forecasts are uncertain; past performance is not indicative of future returns.
• The author or publisher may hold positions in securities mentioned.
• Users should verify information against primary sources (company filings) before acting.
• Investing involves risk of loss; there is no guarantee any target price is achieved.
• Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.